Cutaneous neurofibromas Current clinical and pathologic issues

dc.contributor.authorNicolas Ortonne
dc.contributor.authorPierre Wolkenstein
dc.contributor.authorJaishri O. Blakeley
dc.contributor.authorBruce Korf
dc.contributor.authorScott R. Plotkin
dc.contributor.authorVincent M. Riccardi
dc.contributor.authorDouglas C. Miller
dc.contributor.authorSusan Huson
dc.contributor.authorJuha Peltonen
dc.contributor.authorAndrew Rosenberg
dc.contributor.authorSteven L. Carroll
dc.contributor.authorSharad K. Verma
dc.contributor.authorVictor Mautner
dc.contributor.authorMeena Upadhyaya
dc.contributor.authorAnat Stemmer-Rachamimov
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id35715450
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/35715450
dc.date.accessioned2022-10-28T14:32:52Z
dc.date.available2022-10-28T14:32:52Z
dc.description.abstractObjectiveTo present the current terminology and natural history of neurofibromatosis 1 (NF1) cutaneous neurofibromas (cNF).MethodsNF1 experts from various research and clinical backgrounds reviewed the terms currently in use for cNF as well as the clinical, histologic, and radiographic features of these tumors using published and unpublished data.ResultsNeurofibromas develop within nerves, soft tissue, and skin. The primary distinction between cNF and other neurofibromas is that cNF are limited to the skin whereas other neurofibromas may involve the skin, but are not limited to the skin. There are important cellular, molecular, histologic, and clinical features of cNF. Each of these factors is discussed in consideration of a clinicopathologic framework for cNF.ConclusionThe development of effective therapies for cNF requires formulation of diagnostic criteria that encompass the clinical and histologic features of these tumors. However, there are several areas of overlap between cNF and other neurofibromas that make distinctions between cutaneous and other neurofibromas more difficult, requiring careful deliberation with input across the multiple disciplines that encounter these tumors and ultimately, prospective validation. The ultimate goal of this work is to facilitate accurate diagnosis and meaningful therapeutics for cNF.
dc.format.pagerangeS13
dc.format.pagerangeS5
dc.identifier.jour-issn0028-3878
dc.identifier.olddbid188900
dc.identifier.oldhandle10024/171994
dc.identifier.urihttps://www.utupub.fi/handle/11111/43865
dc.identifier.urnURN:NBN:fi-fe2021042719678
dc.language.isoen
dc.okm.affiliatedauthorPeltonen, Juha
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1212/WNL.0000000000005792
dc.relation.ispartofjournalNeurology
dc.relation.issue2 Suppl. 1
dc.relation.volume91
dc.source.identifierhttps://www.utupub.fi/handle/10024/171994
dc.titleCutaneous neurofibromas Current clinical and pathologic issues
dc.year.issued2018

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
S5.full.pdf
Size:
1.21 MB
Format:
Adobe Portable Document Format
Description:
Publisher's version